


UnitedHealth Group Inc UNH ★★★★ 23 Jul 2025 21:26, UTC

Last Price	Fair Value Estimate	Price/FVE	Market Cap	Economic Moat™	Equity Style Box	Uncertainty	Capital Allocation	ESG Risk Rating Assessment¹
292.51 USD 23 Jul 2025	473.00 USD 22 May 2025 12:07, UTC	0.62	257.12 USD Bil 24 Jul 2025	Narrow	Large Value	High	Standard	★★★★

4 Jun 2025 05:00, UTC

Price vs. Fair Value



Total Return % as of 23 Jul 2025. Last Close as of 23 Jul 2025. Fair Value as of 22 May 2025 12:07, UTC.

Contents

- Analyst Note (24 Jul 2025)
- Business Description
- Business Strategy & Outlook (22 May 2025)
- Bulls Say / Bears Say (22 May 2025)
- Economic Moat (22 May 2025)
- Fair Value and Profit Drivers (22 May 2025)
- Risk and Uncertainty (22 May 2025)
- Capital Allocation (22 May 2025)
- Analyst Notes Archive
- Financials
- ESG Risk
- Appendix
- Research Methodology for Valuing Companies

Important Disclosure

The conduct of Morningstar's analysts is governed by Code of Ethics/Code of Conduct Policy, Personal Security Trading Policy (or an equivalent of), and Investment Research Policy. For information regarding conflicts of interest, please visit: <http://global.morningstar.com/equitydisclosures>.

The primary analyst covering this company does not own its stock.

The ESG Risk Rating Assessment is a representation of Sustainalytics' ESG Risk Rating.

UnitedHealth: Acknowledged DOJ Probe Into Medicare Advantage Program Highlights Risks

Analyst Note Julie Utterback, CFA, Senior Equity Analyst, 24 Jul 2025

After proactively reaching out to the Department of Justice following recent reports in The Wall Street Journal, UnitedHealth announced that it was cooperating with criminal and civil investigations about its Medicare Advantage program. Shares fell about 2% after this announcement.

Why it matters: These now acknowledged investigations highlight key risks that have cut into shares in recent months, and we suspect fines or clawbacks of previous overpayments related to its MA plans are possible if wrongdoing is found.

- UnitedHealth has been facing investigations into its MA practices, like risk-related upcoding, for about a decade, and it has yet to face significant financial consequences. In fact, this spring, a court-appointed special master could find no wrongdoing by the firm.
- So, it remains to be seen if these investigations will result in financial consequences, but we have already included a potential \$20 billion cash outflow in our model and lower Medicare Advantage margins than historical norms to reflect these risks.

The bottom line: We are keeping our fair value estimate for narrow-moat UnitedHealth at \$473 and continue to view shares as undervalued for the risks.

- However, investors should be aware of the elevated uncertainty (High Morningstar Uncertainty Rating) and share volatility that may arise, given ongoing challenges at UnitedHealth.

UnitedHealth Group Inc UNH ★★★★ 23 Jul 2025 21:26, UTC

Last Price	Fair Value Estimate	Price/FVE	Market Cap	Economic Moat™	Equity Style Box	Uncertainty	Capital Allocation	ESG Risk Rating Assessment ¹
292.51 USD 23 Jul 2025	473.00 USD 22 May 2025 12:07, UTC	0.62	257.12 USD Bil 24 Jul 2025	Narrow	Large Value	High	Standard	4 Jun 2025 05:00, UTC

Sector	Industry
Healthcare	Healthcare Plans

Business Description

UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in medical insurance. Along with its insurance assets, UnitedHealth's Optum franchises help create a healthcare services colossus that spans everything from pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.

Coming up: On its July 29 earnings call, it plans to give 2025 guidance under returning CEO Stephen Hemsley, and we think this announcement could act as a catalyst for shares—up or down—as investors clamor for a baseline in the firm's earnings power.

- When Hemsley took the helm in May, UnitedHealth withdrew its April-issued 2025 EPS guidance of \$26.00-\$26.50 (down from \$29.50-\$30.00 previously). FactSet consensus is currently at \$20.75, albeit with a wide range of estimates from \$18 to \$26.
- If guidance appears significantly above consensus, shares could rally, while lower guidance could push shares down further.

Business Strategy & Outlook Julie Utterback, CFA, Senior Equity Analyst, 22 May 2025

UnitedHealth Group operates a top-tier health insurer (UnitedHealthcare), pharmacy benefit manager (Optum Rx), provider (Optum Health), and health analytics franchise (Optum Insight). Historically, this integrated strategy resulted in some of the best returns in the managed care industry that other managed care organizations have attempted to copy, including CVS Health that added Aetna's medical insurance assets to its retail stores and PBM and Cigna that added Express Scripts' PBM assets to medical insurance base. With the alignment of these interests, we think vertically integrated organizations like UnitedHealth have the opportunity to help bend the healthcare cost curve in the US. However, questions continue to swirl around whether UnitedHealth's pursuit of profits outweighs those potential benefits to the system.

UnitedHealth has operated on the leading edge of changes affecting the industry. For example, its 2015 acquisition of Catamaran greatly increased its PBM scale and helped create a more holistic view of a patient's care. That combination of services helps the company offer synergies to clients, such as employers and government programs, that are seeking to lower overall healthcare costs rather than just pharmacy or medical benefits. Adding service providers to the mix should align incentives even further, especially since the firm's outpatient care assets offer significantly lower costs than hospital-based services. United's analytical tools help caregiver and insurer clients pull various healthcare information together to provide an even fuller picture of a patient's health and care options.

By providing those diverse yet connected services, UnitedHealth aims to grow in nearly any regulatory environment. It is shooting for 13%-16% annual earnings growth in the long run, including strong operational growth and capital allocation activities, such as acquisitions and repurchases. While some regulatory scenarios could eventually cut into that mission, we suspect the value that UnitedHealth provides to the US healthcare system will help it remain relevant in the long run.


Bulls Say Julie Utterback, CFA, Senior Equity Analyst, 22 May 2025

- UnitedHealth's strategy of providing medical insurance, pharmacy benefits, and healthcare services should create a powerful alignment of incentives to help clients control their healthcare costs better

UnitedHealth Group Inc UNH ★★★★ 23 Jul 2025 21:26, UTC

Last Price 292.51 USD 23 Jul 2025	Fair Value Estimate 473.00 USD 22 May 2025 12:07, UTC	Price/FVE 0.62	Market Cap 257.12 USD Bil 24 Jul 2025	Economic Moat™  Narrow	Equity Style Box  Large Value	Uncertainty High	Capital Allocation Standard	ESG Risk Rating Assessment ¹  4 Jun 2025 05:00, UTC
---	---	-------------------	---	--	---	---------------------	--------------------------------	---

Competitors



Economic Moat	 Narrow	 None	 None	 Narrow
Currency	USD	USD	USD	USD
Fair Value	473.00 22 May 2025 12:07, UTC	86.00 12 Feb 2025 18:02, UTC	77.00 3 Jul 2025 20:41, UTC	357.00 30 Jan 2025 16:41, UTC
1-Star Price	733.15	133.30	134.75	481.95
5-Star Price	283.80	51.60	38.50	249.90
Assessment	Undervalued 23 Jul 2025	Undervalued 23 Jul 2025	Undervalued 23 Jul 2025	Undervalued 23 Jul 2025
Morningstar Rating	★★★★ 23 Jul 2025 21:26, UTC	★★★★ 23 Jul 2025 21:24, UTC	★★★★ 23 Jul 2025 21:23, UTC	★★★★ 23 Jul 2025 21:22, UTC
Analyst	Julie Utterback, Senior Equity Analyst	Julie Utterback, Senior Equity Analyst	Julie Utterback, Senior Equity Analyst	Julie Utterback, Senior Equity Analyst
Capital Allocation	Standard	Standard	Standard	Standard
Price/Fair Value	0.62	0.72	0.38	0.85
Price/Sales	0.66	0.21	0.09	0.33
Price/Book	2.80	1.01	0.52	2.04
Price/Earning	11.71	13.31	3.77	11.03
Dividend Yield	2.91%	4.30%	0.00%	1.91%
Market Cap	265.35 Bil	78.24 Bil	14.64 Bil	81.30 Bil
52-Week Range	248.88–630.73	43.56–72.51	27.34–80.59	262.03–370.83
Investment Style	Large Value	Large Value	Mid Value	Large Value

than pure-play competitors.

- As the leading provider of Medicare Advantage plans in the US, UnitedHealth should benefit from ongoing demographic shifts and the increasing popularity of these plans among seniors.
- UnitedHealth has managed its balance sheet more conservatively than peers, which should give it more financial flexibility during uncertain periods like the current environment.

Bears Say Julie Utterback, CFA, Senior Equity Analyst, 22 May 2025

- Regulatory scrutiny appears targeted specifically at UnitedHealth, with ongoing antitrust investigations, questions around its risk assessments in Medicare Advantage, and scrutiny of its coverage denial rates in focus.
- The insurance and PBM industries will likely remain targets of regulators aiming to increase health coverage and reduce the healthcare cost burden on society until the US achieves universal, affordable coverage.

UnitedHealth Group Inc UNH ★★★★ 23 Jul 2025 21:26, UTC

Last Price	Fair Value Estimate	Price/FVE	Market Cap	Economic Moat™	Equity Style Box	Uncertainty	Capital Allocation	ESG Risk Rating Assessment ¹
292.51 USD 23 Jul 2025	473.00 USD 22 May 2025 12:07, UTC	0.62	257.12 USD Bil 24 Jul 2025	 Narrow	 Large Value	High	Standard	 4 Jun 2025 05:00, UTC

- The law of large numbers may eventually catch up to this healthcare behemoth, making its 13%-16% earnings growth goal difficult to achieve in the long run.

Economic Moat Julie Utterback, CFA, Senior Equity Analyst, 22 May 2025

Our narrow economic moat rating for UnitedHealth Group reflects our generally narrow-moat view of the US managed care industry, including an unclear outlook for economic profitability outside our 10-year explicit forecast period due to regulatory concerns. Still, as a top-tier US health insurer, pharmacy benefit manager, service provider, and health analytics firm, UnitedHealth possesses enough competitive advantages to generate economic profits for at least the next 10 years, in our view, which is the signature of a narrow-moat firm.

We see a variety of moat sources stemming from its highly diversified business model, but overall, we think cost advantages and network effects are the companywide moat sources.

The Leading US Medical Insurer Benefits From Cost Advantages and Network Effects

In medical insurance, we believe UnitedHealth operates with cost advantages and network effects. Although the firm operates a broad nationwide network, we think UnitedHealth benefits from scale advantages in specific locations, too, which is the key determinant of moats in medical insurance since local scale allows for greater negotiating leverage versus local healthcare suppliers than smaller insurers in each market. Also, when local scale advantages are significant enough, we think UnitedHealth's insurance operations benefit from a network effect. According to the American Medical Association, the share of local insurance markets in the US that were highly concentrated grew to 73% in 2022 from 71% in 2014, with leaders like UnitedHealth likely taking share in those markets due to local market dynamics. For example, in communities where UnitedHealth already enjoys substantial market share, it can offer lower costs or more benefits per member to existing and potential clients than its peers. If that offering is compelling enough, more members will be attracted to UnitedHealth's insurance plans in those communities, and local service providers (such as hospitals and physician groups) will have more incentive to join and offer lower prices to UnitedHealth's insurance networks to gain access to its large, growing membership rolls, creating a network effect.

Top-Tier Pharmacy Benefit Manager Enjoys Switching Costs and Network Effects

UnitedHealth's pharmacy benefit manager, Optum Rx, appears competitively advantaged with switching costs and a network effect present. The top three PBMs process about 80% of US pharmaceutical claims, and we think their historical cost advantages over other players led to their dominance of this market. However, they do not appear to have significant cost advantages over one another any longer. From a moat source perspective, we see evidence of switching costs and network effects at the PBMs that could prevent a big change in the competitive landscape, despite some new

UnitedHealth Group Inc UNH ★★★★ 23 Jul 2025 21:26, UTC

Last Price	Fair Value Estimate	Price/FVE	Market Cap	Economic Moat™	Equity Style Box	Uncertainty	Capital Allocation	ESG Risk Rating Assessment ¹
292.51 USD 23 Jul 2025	473.00 USD 22 May 2025 12:07, UTC	0.62	257.12 USD Bil 24 Jul 2025	Narrow	Large Value	High	Standard	4 Jun 2025 05:00, UTC

entrants emerging. For example, PBM contracts provide some switching costs for clients, with each contract typically lasting about three years on average and retention rates typically in the high 90s. This means client relationships can extend well beyond contractual terms probably due to inertia factors related to limited realistic alternatives.

Also, in recent years we have seen some network effects including cumulative market share increases by the top-tier players and UnitedHealth specifically. Overall, we think clients are most attracted to the discounts they can get on drugs due to a PBM's negotiating power with other stakeholders in this market, primarily drug manufacturers and pharmacies. As more users are attracted to a PBM, drug manufacturers and pharmacies have incentive to offer even larger discounts to benefit from those volume-based discounts, which can help scale-advantaged PBMs like UnitedHealth attract even more users and create a virtuous cycle, or a network effect.

The Largest US Caregiver Is Supported Primarily by Intangible Assets

Optum Health's outpatient services segment—consisting primarily of primary care practices, home healthcare service providers, and ambulatory surgical centers—is the largest caregiver in the US, and as at other top-tier caregivers, we think UnitedHealth's caregiving operations benefit from reputational-related intangible assets. Also, this business helps UnitedHealth align incentives between its insurance operations and providers, which can be powerful in the healthcare industry when done correctly. Optum Health service providers allow the company to better manage the care of its members through preventative measures and encourage the use of lower-cost-of-care sites, which can result in significantly lower costs relative to an acute hospital setting, for example.

Healthcare IT Solutions Are Derived From UnitedHealth's Data-Based Solutions

Through its health-related benefits and service businesses, UnitedHealth has amassed a wealth of data that it monetizes through its Optum Insight business. The company's analytical tools and services aim to improve care quality and improve efficiency in the healthcare system through a variety of intangible asset-derived solutions, including population health and risk analytics, consulting services to improve clinical performance and reduce administrative costs, and revenue cycle management tools. The company has previously claimed that its solutions are used by about 4 out of every 5 hospitals and about 3 out of every 4 health insurance plans, highlighting the expansive reach of its influence across the US health system. Switching costs can arise at customers that may be reluctant to switch suppliers in key back-office processes. Also, while it is the smallest business from a revenue perspective, its operating margins are the firm's highest and similar to those of other IT services and solutions companies. We think this highly profitable business adds to UnitedHealth's ability to generate returns on invested capital over capital costs.

Regulatory Concerns May Create Mild Headwinds Primarily in Medicaid and PBM

UnitedHealth Group Inc UNH ★★★★ 23 Jul 2025 21:26, UTC

Last Price	Fair Value Estimate	Price/FVE	Market Cap	Economic Moat™	Equity Style Box	Uncertainty	Capital Allocation	ESG Risk Rating Assessment ¹
292.51 USD 23 Jul 2025	473.00 USD 22 May 2025 12:07, UTC	0.62	257.12 USD Bil 24 Jul 2025	Narrow	Large Value	High	Standard	4 Jun 2025 05:00, UTC

Our narrow moat rating for UnitedHealth is informed by an analysis of potential changes to the US healthcare system, which are possible due to environmental, social, and governance concerns around access to basic healthcare services. Near-term regulatory changes being considered after the 2024 election probably will not significantly dent the firm's industry-leading economic profitability, by our estimates. Beyond the Medicare Advantage-related regulatory risks that we have incorporated into our base-case scenario, we see mid-single-digit risks to operating profits primarily due to UnitedHealth's top-tier exposure to Medicaid and the PBM industry, which appear in the line of fire for regulators soon. Overall though, given how strong its economic margins are, we would be surprised to see them fall anywhere close to capital costs in the near or long term.

Fair Value and Profit Drivers Julie Utterback, CFA, Senior Equity Analyst, 22 May 2025

We are reducing our fair value estimate on UnitedHealth to \$473 per share, from \$530 previously, based on our reduced near- and long-term expectations for UnitedHealth's insurance businesses including MA (8%) and by the potential \$20 billion clawback in Medicare Advantage-related payments (3%).

Through 2029, we assume revenue grows 7% and adjusted earnings per share grow 8% compounded annually, with the latter higher than revenue growth due to share repurchases. Our EPS expectation is significantly below management's long-term goal of 13%-16% due primarily to expected weakness in 2025, which includes a 17% drop in its adjusted EPS. Beyond that, we think the company can return to its targeted midteens growth goals for a few years before decelerating to the low double digits in the outer years of our 10-year forecast period. Of note, management's long-term goals include capital allocation activities like share repurchases and acquisitions. While we include share repurchases in our estimates, we do not include unannounced acquisitions, so that may be one reason why our expectations are often below UnitedHealth's long-term target range.

Also of note, ongoing regulatory concerns, such as potential Medicaid spending cuts and potential changes to its pharmacy benefit management business model, represent a mid-single-digit percentage headwind to ongoing profits on a probability-adjusted basis, which could cut into our fair value estimate further, if enacted.

Risk and Uncertainty Julie Utterback, CFA, Senior Equity Analyst, 22 May 2025

In May 2025, we raised our Uncertainty Rating on UnitedHealth to High from Medium previously on company-specific challenges that continue to mount at the organization and create a murky profit outlook in addition to broader regulatory concerns.

Overall, potential healthcare policy changes could create ESG-related risks for UnitedHealth, especially during election cycles, as access to universal, affordable coverage remains a key concern of the US public. For example, regulators could continue to put pressure on profit margins in this middleman

UnitedHealth Group Inc UNH ★★★★ 23 Jul 2025 21:26, UTC

Last Price	Fair Value Estimate	Price/FVE	Market Cap	Economic Moat™	Equity Style Box	Uncertainty	Capital Allocation	ESG Risk Rating Assessment ¹
292.51 USD 23 Jul 2025	473.00 USD 22 May 2025 12:07, UTC	0.62	257.12 USD Bil 24 Jul 2025	Narrow	Large Value	High	Standard	4 Jun 2025 05:00, UTC

industry, which could reduce long-term growth prospects. The top-tier PBMs, including UnitedHealth's Optum Rx business, are being scrutinized by both Republicans and Democrats for a lack of transparency particularly around rebates and spread-based pricing, which could be eliminated eventually. Republicans also aim to reduce spending in key end markets, such as Medicaid, which could eat into UnitedHealth's prospects as well.

Company-specific challenges continue to mount for UnitedHealth, too, including questions around its coverage decisions, risk assessments in Medicare Advantage, conflicts between its medical insurance and Optum operations, and surging medical utilization. Although we suspect investors may eventually appreciate that new CEO Stephen Hemsley is taking a firmer grip on UnitedHealth while the major inputs for 2026's results can still be influenced, the murky outlook for 2025 and executive suite shakeup inject more uncertainty into the situation.

Capital Allocation Julie Utterback, CFA, Senior Equity Analyst, 22 May 2025

We are reducing our Capital Allocation Rating on UnitedHealth to Standard, from Exemplary previously, to reflect that management may have been too aggressive with some of its business practices to maximize profits and may have permanently impaired shareholder value in the process. That cut into our previously exceptional view of UnitedHealth's investments. We still think the firm's balance sheet is sound and its shareholder distributions are appropriate.

Overall, UnitedHealth's capital allocation has historically ranked in the top echelon in healthcare services, in our opinion. However, management's attempts to maximize profits may have pushed up risk assessments in Medicare Advantage and may have led to less generous coverage decisions than patients deserved throughout its medical insurance operations. Because of these factors, UnitedHealth may be subject to large cash outflows from government clawbacks or lower margins than it previously anticipated. The company's suspended 2025 outlook after CEO Andrew Witty left and the potential for a further mismatch in rates and utilization in insurance along with the Change network outage in early 2024 also contributed to a stain on its execution record. Those factors have tempered our view of UnitedHealth's investments.

More positively, UnitedHealth's largely organic investment strategy has allowed it to maintain a flexible balance sheet. For example, at the end of 2024, gross leverage stood around 2 times. We do not believe ongoing acquisitions have materially affected the company's financial health. Overall, we think this balance sheet strength should help UnitedHealth manage potential financial hurdles, including a big clawback of payments in Medicare Advantage.

UnitedHealth also distributes cash to shareholders appropriately, in our opinion. It typically pays out around 30% of its profits in dividends each year, and we expect a healthy payout ratio to continue, although the dividend may not grow until its earnings power and growth trajectory are assured. It also repurchases shares regularly, which can add to bottom-line growth on a per share basis. Given recent

UnitedHealth Group Inc UNH ★★★★ 23 Jul 2025 21:26, UTC

Last Price	Fair Value Estimate	Price/FVE	Market Cap	Economic Moat™	Equity Style Box	Uncertainty	Capital Allocation	ESG Risk Rating Assessment ¹
292.51 USD 23 Jul 2025	473.00 USD 22 May 2025 12:07, UTC	0.62	257.12 USD Bil 24 Jul 2025	Narrow	Large Value	High	Standard	4 Jun 2025 05:00, UTC

share prices below fair value, UnitedHealth may even be able to create a bit of intrinsic value in the short term versus its historic pattern of buying above or near fair value, too. However, given the uncertainty around its ongoing cash flows, we would not be surprised to see the firm hoard cash for the near future.

Analyst Notes Archive

UnitedHealth: Shares Dive on Wall Street Journal Report of Criminal Probe in Medicare Advantage

Julie Utterback, CFA, Senior Equity Analyst, 15 May 2025

The Wall Street Journal reported on May 14 that a criminal component had been added to an already-reported civil investigation of UnitedHealth's risk-rating practices in Medicare Advantage. UnitedHealth later responded that it had not been notified of the criminal probe. Why it matters: After the media report but before UnitedHealth's rebuttal, shares were down another 8% in after-hours trading, crashing further in a dismal week for investors that already saw its CEO leave and 2025 guidance suspended. The potential for Medicare fraud at the largest Medicare Advantage insurer is spooking investors, and if wrongdoing is eventually found, the monetary damages could be stiff. Previous assertions under Andrew Witty that risk assessments would solve its current profit challenges look dubious. The diversity of UnitedHealth's operations should shield it somewhat. About half of profits come from medical insurance and only about 15% of its global medical membership comes from Medicare Advantage, which looks disproportionately low relative to recent share movement. The bottom line: After raising our Uncertainty Rating to High following the management and guidance announcement earlier this week, we are making no further changes to our views of narrow-moat UnitedHealth. Positively, UnitedHealth maintains a conservative balance sheet, including gross debt/EBITDA of roughly 2 times and credit ratings in the single-A category. Financially, we suspect the company should be able to ride out gathering storms. Shares appear significantly undervalued to us at these levels, but investors should be aware of the elevated uncertainty and potential for share volatility, especially given ongoing regulatory challenges broadly for the industry and specifically for UnitedHealth. Bears say: UnitedHealth shares have fallen by half in just a month, and current prices imply a further deterioration of profits representing nearly half of its medical insurance operations in the near term.

UnitedHealth: Pulls 2025 Outlook and Replaces CEO With Chair and Former CEO Stephen Hemsley

Julie Utterback, CFA, Senior Equity Analyst, 13 May 2025

UnitedHealth shares fell nearly 10% in early trading May 13 after the company pulled its 2025 guidance on surging medical utilization and replaced CEO Andrew Witty with its current chairman and former CEO from 2006-17, Stephen Hemsley. Why it matters: Challenges continue to pile up for UnitedHealth, which has caused shares to drop from over \$600 on the day of its key insurance executive's killing in early December to below \$350 per share in pre-market trading May 13. Since December, UnitedHealth

UnitedHealth Group Inc UNH ★★★★ 23 Jul 2025 21:26, UTC

Last Price	Fair Value Estimate	Price/FVE	Market Cap	Economic Moat™	Equity Style Box	Uncertainty	Capital Allocation	ESG Risk Rating Assessment ¹
292.51 USD 23 Jul 2025	473.00 USD 22 May 2025 12:07, UTC	0.62	257.12 USD Bil 24 Jul 2025	Narrow	Large Value	High	Standard	4 Jun 2025 05:00, UTC

shares have re-rated on broad regulatory concerns and company-specific questions around its coverage decisions, risk ratings in Medicare Advantage, conflicts between its medical insurance and Optum operations, and surging medical utilization. Although we suspect investors may eventually appreciate Hemsley taking a firmer grip on UnitedHealth while the major inputs for 2026's results can still be influenced, the murky outlook for 2025 and executive suite shakeup inject more uncertainty into the situation. The bottom line: While we are keeping our fair value estimate at \$530 per share for now, we are raising our Uncertainty Rating to High from Medium to reflect the company-specific challenges that UnitedHealth faces, especially in the near term. Our narrow moat rating on UnitedHealth has not changed, and UnitedHealth remains the strongest managed care organization we cover with a significant margin for executional error like we are seeing currently. Although we are keeping our Capital Allocation Rating at Exemplary, we may reconsider that rating if Hemsley's team cannot turn around the company's execution in its risk-related businesses in 2026 and beyond. Bulls say: While the 2025 outlook suspension is disappointing, management continued to highlight that it aims to eventually return to its earnings growth target of 13% to 16%. Returning to that growth trajectory in the long run would make current share prices look very attractive.

Healthcare Services: Medicaid and PBMs Still Under Fire in Updated Regulatory Moves Julie Utterback, CFA, Senior Equity Analyst, 12 May 2025

On May 11 and 12, Republicans revealed updated regulatory stances that included plans to lower drug prices and pull back on Medicaid spending by about \$715 billion over the next 10 years versus \$880 billion expected previously. Why it matters: In early trading, top-tier Medicaid insurer Elevance and healthcare service providers like HCA and Tenet rose in the low single digits, as the potential Medicaid changes look better than feared. However, PBM-focused firms, like Cigna and CVS, fell on the drug pricing efforts. On May 11, Republican House members revealed a proposed bill that looks likely to cut Medicaid spending less than the initial goal, which may moderately buoy the profits of Medicaid-reliant service providers and managed care organizations. On May 12, President Donald Trump signed an order to lower US drug prices, which could eliminate a key function that PBMs provide to clients, as the government looks likely to undertake drug price negotiations or set prices to lower, most-favored-nation levels. The bottom line: We are keeping our fair value estimates intact for now, as Congress still needs to vote on Medicaid cuts, which are controversial even in Republican districts. Also, few details are known about how drug pricing negotiations would actually work, including how broadly they could reach. If Medicaid legislation passes as the House proposes, we would see the most risk at no-moat Centene, a Medicaid and individual exchange plan provider that faces a high-single-digit fair value cut under this bill plus the potential expiration of individual exchange subsidies. Narrow-moat Cigna faces the most downside risk if the US government starts negotiating drug prices, which is currently a key PBM function. It remains to be seen how broadly this order could reach beyond government programs, though, and service bundling may protect PBMs somewhat.

UnitedHealth Group Inc UNH ★★★★ 23 Jul 2025 21:26, UTC

Last Price	Fair Value Estimate	Price/FVE	Market Cap	Economic Moat™	Equity Style Box	Uncertainty	Capital Allocation	ESG Risk Rating Assessment ¹
292.51 USD 23 Jul 2025	473.00 USD 22 May 2025 12:07, UTC	0.62	257.12 USD Bil 24 Jul 2025	Narrow	Large Value	High	Standard	4 Jun 2025 05:00, UTC

UnitedHealth Earnings: Weak Start to 2025 Cuts Into Near-Term Outlook and Fair Value Estimate

Julie Utterback, CFA, Senior Equity Analyst, 17 Apr 2025

Despite 10% revenue growth led by its medical insurer (12%) and PBM (14%), UnitedHealth lowered its 2025 guidance after a weak first quarter included only 4% adjusted EPS growth due to surging medical costs. Why it matters: Management lowered its 2025 outlook due to this weak start to the year, causing shares to fall about 20% in early trading on April 17. The firm pointed to two major factors that cut its 2025 adjusted EPS view to \$26.00-\$26.50, down from \$29.50-\$30.00 previously. First, higher medical costs in its Medicare Advantage business contributed to its weak first-quarter profits. UnitedHealth now expects that elevated utilization to continue hurting its medical insurance profits through 2025. Second, its provider, Optum Health, delivered weak results, as new patients chose its value-based care providers after key insurance plans exited certain geographies, creating a situation where UnitedHealth is treating patients at lower rates than it believes is fair for the risk. The bottom line: We are reducing our near-term expectations for UnitedHealth to reflect this elevated utilization in medical insurance and weak Optum Health-related trends, which cut our fair value estimate 10% to \$530 per share. We continue to see shares as about fairly valued. Our narrow moat rating on UnitedHealth has not changed, and UnitedHealth remains the strongest managed care organization we cover with significant margin for executional error like we are currently seeing. Although we are keeping our Capital Allocation Rating at Exemplary for now, executional errors like these are starting to weigh on our investment assessment. Bulls say: While the 2025 outlook cut was disappointing, management highlighted initiatives that could help it get back to its annual earnings growth target of 13% to 16% in the long run. Also, as a US-based and US-focused firm, UnitedHealth looks largely immune to tariffs.

Medical Services: MCOs Immune, but Tariffs May Cause Near-Term Stress at Providers and Suppliers Julie Utterback, CFA, Senior Equity Analyst, 10 Apr 2025

Over the past week, tariff-related news has created significant volatility in the US market, including in medical services-related firms like managed care organizations, caregivers, and medical suppliers. Why it matters: Some of these companies look largely tariff-proof, including managed care organizations like UnitedHealth, while others look merely recession-resistant, including caregivers like HCA and medical suppliers like Baxter. As US-based and US-focused firms, MCOs look largely immune to tariffs. The only concern could be in the near term if the US economy falls into recession and causes a mix shift in medical insurance members from employer to lower-margin Medicaid plans. Providers and medical suppliers could feel more direct effects of higher costs in their supply chains due to tariffs. Of these two, medical suppliers face the more significant profit risk due to multiyear contracts with clients and potential delays in large equipment orders from clients. The bottom line: In February, we reduced our fair value estimate for medical supplier Baxter on near-term tariff concerns, and we do not anticipate making further changes to it. We see most of the medical services firms we cover (MCOs, providers, and

UnitedHealth Group Inc UNH ★★★★ 23 Jul 2025 21:26, UTC

Last Price	Fair Value Estimate	Price/FVE	Market Cap	Economic Moat™	Equity Style Box	Uncertainty	Capital Allocation	ESG Risk Rating Assessment ¹
292.51 USD 23 Jul 2025	473.00 USD 22 May 2025 12:07, UTC	0.62	257.12 USD Bil 24 Jul 2025	Narrow	Large Value	High	Standard	4 Jun 2025 05:00, UTC

suppliers) as undervalued currently. In managed care, our moat ratings were all recently updated during our moat staleness review process. UnitedHealth, Humana, Elevance, and Cigna remain at narrow, while CVS and Centene are now at none. In providers and suppliers, most of our moat ratings were also reviewed in late 2024 or early 2025. They remain narrow for Baxter, DaVita, Fresenius Medical Care, HCA, and Tenet and none for ICU Medical. Coming up: We plan to keep a close eye on how hospital capital expenditure budgets develop and how they could affect medical suppliers in a scenario where tariffs create sticker shock on large equipment especially. Also, investors should be aware of other regulatory factors that could affect the MCOs.


MCOs: Strong Final 2026 Rate Notice for Medicare Advantage Boosts Undervalued Shares Julie Utterback, CFA, Senior Equity Analyst, 7 Apr 2025

Late on April 7, the Centers for Medicare and Medicaid Services released its final reimbursement rate notice for Medicare Advantage, highlighting an expected change in per capita revenue of 5.06% in 2026 even after risk-related adjustments. This is up from 2.23% in the January initial rate notice. Why it matters: This announcement represents a first look at how Republicans plan to regulate rates in the important Medicare Advantage market. It appears they will be more generous than Democrats have been in recent years, which is a welcome change of pace for the MCOs we cover. In after-hours trading, MA-focused insurer Humana traded up about 12%, MA-leader UnitedHealth rose about 6%, and top-tier MA insurer CVS increased about 7%. Even lower-tier MA players Elevance (up 7%) and Centene (up 4%) rose on the news. Also, Cigna, which has no exposure to Medicare Advantage after selling off that business to Health Care Service Corporation in March, inexplicably rose 1% after hours, generally benefiting from the improving market sentiment in the industry. The bottom line: In our valuation models, we previously suspected that the recent lean years in Medicare Advantage under Democrats would give way to more normalized trends eventually, so this good start under Republican rule merely starts that normalization process for MA insurers. We are not changing any of our fair value estimates in the industry and continue to view most of the MCOs we cover as moderately undervalued, including MA-focused insurer Humana which still trades at a roughly 30% discount to fair value even following the after-hours rally. Our moat ratings were all recently updated during our moat staleness review process and remain narrow for UnitedHealth, Humana, Elevance, and Cigna and none for CVS and Centene. ■

UnitedHealth Group Inc UNH ★★★★ 23 Jul 2025 21:26, UTC


Competitors Price vs. Fair Value

CVS Health Corp CVS



Total Return % as of 23 Jul 2025. Last Close as of 23 Jul 2025. Fair Value as of 12 Feb 2025 18:02, UTC.

Centene Corp CNC




Total Return % as of 23 Jul 2025. Last Close as of 23 Jul 2025. Fair Value as of 3 Jul 2025 20:41, UTC.

UnitedHealth Group Inc UNH ★★★★ 23 Jul 2025 21:26, UTC

Competitors Price vs. Fair Value

The Cigna Group CI



Total Return % as of 23 Jul 2025. Last Close as of 23 Jul 2025. Fair Value as of 30 Jan 2025 16:41, UTC.

UnitedHealth Group Inc UNH ★★★★

23 Jul 2025 21:26, UTC

Last Price	Fair Value Estimate	Price/FVE	Market Cap	Economic Moat™	Equity Style Box	Uncertainty	Capital Allocation	ESG Risk Rating Assessment ¹
292.51 USD 23 Jul 2025	473.00 USD 22 May 2025 12:07, UTC	0.62	257.12 USD Bil 24 Jul 2025	Narrow	Large Value	High	Standard	 4 Jun 2025 05:00, UTC

Morningstar Valuation Model Summary

Financials as of 21 May 2025

	Actual			Forecast				
	2022	2023	2024	2025	2026	2027	2028	2029
Fiscal Year, ends 31 Dec								
Revenue (USD Mil)	324,162	371,622	400,278	449,181	488,625	516,256	542,963	567,368
Operating Income (USD Mil)	28,435	32,358	32,287	29,942	33,264	37,130	41,825	47,054
EBITDA (USD Mil)	31,835	36,330	28,076	34,434	38,150	22,252	47,254	52,727
Adjusted EBITDA (USD Mil)	33,062	37,822	42,948	36,018	39,873	44,113	49,169	54,728
Net Income (USD Mil)	20,120	22,381	14,405	19,668	22,198	9,465	28,651	32,630
Adjusted Net Income (USD Mil)	21,081	23,567	25,699	20,904	23,542	26,517	30,145	34,190
Free Cash Flow To The Firm (USD Mil)	1,946	15,546	9,338	20,898	24,597	10,220	28,866	32,236
Weighted Average Diluted Shares Outstanding (Mil)	950	938	929	915	899	881	863	846
Earnings Per Share (Diluted) (USD)	21.18	23.86	15.51	21.49	24.69	10.74	33.18	38.56
Adjusted Earnings Per Share (Diluted) (USD)	22.19	25.12	27.66	22.84	26.19	30.10	34.91	40.41
Dividends Per Share (USD)	6.31	7.21	8.11	8.11	8.11	8.11	10.47	12.12

Margins & Returns as of 21 May 2025

	Actual			Forecast					
	3 Year Avg	2022	2023	2024	2025	2026	2027	2028	2029
Operating Margin %	7.8	8.8	8.7	8.1	6.7	6.8	7.2	7.7	8.3
EBITDA Margin %	—	9.8	9.8	7.0	7.7	7.8	4.3	8.7	9.3
Adjusted EBITDA Margin %	—	10.2	10.2	10.7	8.0	8.2	8.5	9.1	9.7
Net Margin %	5.3	6.2	6.0	3.6	4.4	4.5	1.8	5.3	5.8
Adjusted Net Margin %	6.4	6.5	6.3	6.4	4.7	4.8	5.1	5.6	6.0
Free Cash Flow To The Firm Margin %	2.4	0.6	4.2	2.3	4.7	5.0	2.0	5.3	5.7

Growth & Ratios as of 21 May 2025

	Actual			Forecast					
	3 Year CAGR	2022	2023	2024	2025	2026	2027	2028	2029 5 Year CAGR
Revenue Growth %	11.7	12.7	14.6	7.7	12.2	8.8	5.7	5.2	4.5
Operating Income Growth %	10.4	18.6	13.8	-0.2	-7.3	11.1	11.6	12.6	12.5
EBITDA Growth %	3.0	17.6	14.1	22.7	22.7	10.8	-41.7	112.4	11.6
Adjusted EBITDA Growth %	15.0	17.2	14.4	13.6	-16.1	10.7	10.6	11.5	11.3
Earnings Per Share Growth %	-5.0	17.1	12.7	-35.0	38.6	14.9	-56.5	208.9	16.2
Adjusted Earnings Per Share Growth %	-5.0	16.7	13.2	10.1	-17.4	14.6	14.9	16.0	15.7

Valuation as of 21 May 2025

	Actual			Forecast				
	2022	2023	2024	2025	2026	2027	2028	2029
Price/Earning	23.9	21.0	18.3	12.8	11.2	9.7	8.4	7.2
Price/Sales	1.5	1.3	1.2	0.6	0.5	0.5	0.5	0.5
Price/Book	6.5	5.6	5.1	2.8	2.6	2.9	2.6	2.4
Price/Cash Flow	—	—	—	—	—	—	—	—
EV/EBITDA	15.2	13.4	11.7	8.7	7.8	7.1	6.4	5.7
EV/EBIT	17.6	15.6	15.6	10.4	9.4	8.4	7.5	6.6
Dividend Yield %	1.2	1.4	1.6	2.8	2.8	2.8	3.6	4.1
Dividend Payout %	28.4	28.7	29.3	35.5	31.0	26.9	30.0	30.0
Free Cash Flow Yield %	—	—	—	—	—	—	—	—

Operating Performance / Profitability as of 21 May 2025

	Actual			Forecast				
	2022	2023	2024	2025	2026	2027	2028	2029
Fiscal Year, ends 31 Dec								
ROA %	8.2	8.2	4.8	6.3	6.7	2.9	8.4	9.2
ROE %	23.3	22.6	14.0	18.3	19.7	9.2	26.2	27.7
ROIC %	22.7	21.9	17.8	15.6	16.6	17.5	18.5	19.5

UnitedHealth Group Inc UNH ★★★★ 23 Jul 2025 21:26, UTC

Last Price	Fair Value Estimate	Price/FVE	Market Cap	Economic Moat™	Equity Style Box	Uncertainty	Capital Allocation	ESG Risk Rating Assessment ¹
292.51 USD 23 Jul 2025	473.00 USD 22 May 2025 12:07 UTC	0.62	257.12 USD Bil 24 Jul 2025	Narrow	Large Value	High	Standard	 4 Jun 2025 05:00, UTC

Financial Leverage (Reporting Currency)	Actual			Forecast				
	2022	2023	2024	2025	2026	2027	2028	2029
Fiscal Year, ends 31 Dec								
Debt/Capital %	10.4	11.4	14.2	13.8	13.2	12.1	11.7	11.3
Assets/Equity	2.8	2.8	2.9	2.9	2.9	3.2	3.1	3.0
Net Debt/EBITDA	0.9	0.9	1.7	1.2	1.0	2.2	0.9	0.6
Total Debt/EBITDA	1.7	1.7	1.8	2.0	1.8	1.6	1.4	1.3
EBITDA/ Net Interest Expense	15.8	11.7	11.0	9.9	10.9	11.8	12.9	14.2

Forecast Revisions as of 22 May 2025	2025		2026		2027	
Prior data as of 19 May 2025	Current	Prior	Current	Prior	Current	Prior
Fair Value Estimate Change (Trading Currency)	473.00	524.91	—	—	—	—
Revenue (USD Mil)	449,181	449,181	488,625	503,310	516,256	540,027
Operating Income (USD Mil)	29,942	32,904	33,264	37,872	37,130	41,834
EBITDA (USD Mil)	36,018	38,980	39,873	44,680	44,113	49,139
Net Income (USD Mil)	20,904	23,214	23,542	27,176	26,517	30,251
Earnings Per Share (Diluted) (USD)	21.49	24.02	24.69	28.69	10.74	32.65
Adjusted Earnings Per Share (Diluted) (USD)	22.84	25.37	26.19	30.23	30.10	34.33
Dividends Per Share (USD)	8.11	8.11	8.11	8.11	8.11	8.11

Key Valuation Drivers as of 21 May 2025		USD Mil
Cost of Equity %	9.0	
Pre-Tax Cost of Debt %	5.8	185,190
Weighted Average Cost of Capital %	8.3	71,368
Long-Run Tax Rate %	21.5	241,135
Stage II EBI Growth Rate %	5.0	497,694
Stage II Investment Rate %	30.0	
Perpetuity Year	15	


Discounted Cash Flow Valuation as of 21 May 2025	
Present Value Stage I	
Present Value Stage II	
Present Value Stage III	
Total Firm Value	497,694
Cash and Equivalents	266
Debt	76,904
Other Adjustments	0
Equity Value	421,056
Projected Diluted Shares	915
Fair Value per Share (USD)	473.00

UnitedHealth Group Inc UNH ★★★★ 23 Jul 2025 21:26, UTC

Last Price	Fair Value Estimate	Price/FVE	Market Cap	Economic Moat™	Equity Style Box	Uncertainty	Capital Allocation	ESG Risk Rating Assessment¹
292.51 USD 23 Jul 2025	473.00 USD 22 May 2025 12:07, UTC	0.62	257.12 USD Bil 24 Jul 2025	Narrow	Large Value	High	Standard	 4 Jun 2025 05:00, UTC

ESG Risk Rating Breakdown

Exposure




● Subject ○ Subindustry (35.0)

34.1
Low

0
Medium
High

Management



53.2%
Strong

100
Strong
Average
Weak

- Exposure represents a company's vulnerability to ESG risks driven by their business model
- Exposure is assessed at the Subindustry level and then specified at the company level
- Scoring ranges from 0-55+ with categories of low, medium, and high-risk exposure

- Management measures a company's ability to manage ESG risks through its commitments and actions
- Management assesses a company's efficiency on ESG programs, practices, and policies
- Management score ranges from 0-100% showing how much manageable risk a company is managing

ESG Risk Rating



Negligible Low Medium High Severe

ESG Risk Ratings measure the degree to which a company's value is impacted by environmental, social, and governance risks, by evaluating the company's ability to manage the ESG risks it faces.

1. A company's Exposure to material ESG issues 2. Unmanageable Risk refers to risks that are inherent to a particular business model that cannot be managed by programs or initiatives 3. Managed Risk = Manageable Risk multiplied by a Management score of 53.2% 4. Management Gap assesses risks that are not managed, but are considered manageable 5. ESG Risk Rating Assessment = Overall Unmanaged Risk + Unmanageable Risk

ESG Risk Rating Assessment⁵



ESG Risk Rating is of Jun 04, 2025. Highest Controversy Level is as of Jul 08, 2025. Sustainalytics Subindustry: Managed Health Care. Sustainalytics provides Morningstar with company ESG ratings and metrics on a monthly basis and as such, the ratings in Morningstar may not necessarily reflect current Sustainalytics' scores for the company. For the most up to date rating and more information, please visit: sustainalytics.com/esg-ratings/.

Peer Analysis 04 Jun 2025

Company Name	Exposure	Management	ESG Risk Rating
UnitedHealth Group Inc	34.1 Low	53.2 Strong	16.9 Low
Centene Corp	36.5 Medium	60.5 Strong	15.4 Low
The Cigna Group	34.8 Low	76.1 Strong	9.7 Negligible
CVS Health Corp	38.6 Medium	58.9 Strong	17.1 Low
Humana Inc	37.2 Medium	60.7 Strong	15.8 Low

Appendix

Historical Morningstar Rating

UnitedHealth Group Inc UNH 23 Jul 2025 21:26, UTC

Dec 2025	Nov 2025	Oct 2025	Sep 2025	Aug 2025	Jul 2025	Jun 2025	May 2025	Apr 2025	Mar 2025	Feb 2025	Jan 2025
—	—	—	—	—	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★
Dec 2024	Nov 2024	Oct 2024	Sep 2024	Aug 2024	Jul 2024	Jun 2024	May 2024	Apr 2024	Mar 2024	Feb 2024	Jan 2024
★★★★★	★★★★	★★★★	★★★★	★★★★	★★★★	★★★★	★★★★	★★★★	★★★★	★★★★	★★★★
Dec 2023	Nov 2023	Oct 2023	Sep 2023	Aug 2023	Jul 2023	Jun 2023	May 2023	Apr 2023	Mar 2023	Feb 2023	Jan 2023
★★★★	★★★★	★★★	★★★★	★★★★	★★★★	★★★★	★★★★	★★★★	★★★★	★★★★	★★★★
Dec 2022	Nov 2022	Oct 2022	Sep 2022	Aug 2022	Jul 2022	Jun 2022	May 2022	Apr 2022	Mar 2022	Feb 2022	Jan 2022
★★★	★★	★★	★★	★★	★★	★★	★★	★★	★★	★★	★★
Dec 2021	Nov 2021	Oct 2021	Sep 2021	Aug 2021	Jul 2021	Jun 2021	May 2021	Apr 2021	Mar 2021	Feb 2021	Jan 2021
★★★	★★	★★	★★	★★	★★	★★	★★	★★	★★	★★	★★
Dec 2020	Nov 2020	Oct 2020	Sep 2020	Aug 2020	Jul 2020	Jun 2020	May 2020	Apr 2020	Mar 2020	Feb 2020	Jan 2020
★★★★★	★★★	★★★★	★★★★	★★★★	★★★★	★★★★	★★★★	★★★★	★★★★	★★★★	★★★★

CVS Health Corp CVS 23 Jul 2025 21:24, UTC

Dec 2025	Nov 2025	Oct 2025	Sep 2025	Aug 2025	Jul 2025	Jun 2025	May 2025	Apr 2025	Mar 2025	Feb 2025	Jan 2025
—	—	—	—	—	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★
Dec 2024	Nov 2024	Oct 2024	Sep 2024	Aug 2024	Jul 2024	Jun 2024	May 2024	Apr 2024	Mar 2024	Feb 2024	Jan 2024
★★★★★★	★★★★★★	★★★★★★	★★★★★★	★★★★★★	★★★★★★	★★★★★★	★★★★★★	★★★★★★	★★★★★★	★★★★★★	★★★★★★
Dec 2023	Nov 2023	Oct 2023	Sep 2023	Aug 2023	Jul 2023	Jun 2023	May 2023	Apr 2023	Mar 2023	Feb 2023	Jan 2023
★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★
Dec 2022	Nov 2022	Oct 2022	Sep 2022	Aug 2022	Jul 2022	Jun 2022	May 2022	Apr 2022	Mar 2022	Feb 2022	Jan 2022
★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★
Dec 2021	Nov 2021	Oct 2021	Sep 2021	Aug 2021	Jul 2021	Jun 2021	May 2021	Apr 2021	Mar 2021	Feb 2021	Jan 2021
★★★★	★★★	★★★	★★★	★★★	★★★	★★★	★★★	★★★	★★★	★★★	★★★
Dec 2020	Nov 2020	Oct 2020	Sep 2020	Aug 2020	Jul 2020	Jun 2020	May 2020	Apr 2020	Mar 2020	Feb 2020	Jan 2020
★★★★★	★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★

Centene Corp CNC 23 Jul 2025 21:23, UTC

Dec 2025	Nov 2025	Oct 2025	Sep 2025	Aug 2025	Jul 2025	Jun 2025	May 2025	Apr 2025	Mar 2025	Feb 2025	Jan 2025
—	—	—	—	—	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★
Dec 2024	Nov 2024	Oct 2024	Sep 2024	Aug 2024	Jul 2024	Jun 2024	May 2024	Apr 2024	Mar 2024	Feb 2024	Jan 2024
★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★
Dec 2023	Nov 2023	Oct 2023	Sep 2023	Aug 2023	Jul 2023	Jun 2023	May 2023	Apr 2023	Mar 2023	Feb 2023	Jan 2023
★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★
Dec 2022	Nov 2022	Oct 2022	Sep 2022	Aug 2022	Jul 2022	Jun 2022	May 2022	Apr 2022	Mar 2022	Feb 2022	Jan 2022
★★★	★★★	★★★	★★★	★★★	★★★	★★★	★★★	★★★	★★★	★★★	★★★
Dec 2021	Nov 2021	Oct 2021	Sep 2021	Aug 2021	Jul 2021	Jun 2021	May 2021	Apr 2021	Mar 2021	Feb 2021	Jan 2021
★★★	★★★	★★★	★★★	★★★	★★★	★★★	★★★	★★★	★★★	★★★	★★★
Dec 2020	Nov 2020	Oct 2020	Sep 2020	Aug 2020	Jul 2020	Jun 2020	May 2020	Apr 2020	Mar 2020	Feb 2020	Jan 2020
★★★★★	★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	★★★★★	—	—	—	—

The Cigna Group CI 23 Jul 2025 21:22, UTC

Dec 2025 —	Nov 2025 —	Oct 2025 —	Sep 2025 —	Aug 2025 —	Jul 2025 ★★★★★	Jun 2025 ★★★★★	May 2025 ★★★★★	Apr 2025 ★★★	Mar 2025 ★★★★★	Feb 2025 ★★★★★	Jan 2025 ★★★★★
Dec 2024 ★★★★★	Nov 2024 ★★★★★	Oct 2024 ★★★★★	Sep 2024 ★★★	Aug 2024 ★★★	Jul 2024 ★★★	Jun 2024 ★★★	May 2024 ★★★	Apr 2024 ★★★	Mar 2024 ★★★	Feb 2024 ★★★	Jan 2024 ★★★★★
Dec 2023 ★★★★★	Nov 2023 ★★★★★	Oct 2023 ★★★★★	Sep 2023 ★★★★★	Aug 2023 ★★★★★	Jul 2023 ★★★★★	Jun 2023 ★★★★★	May 2023 ★★★★★	Apr 2023 ★★★★★	Mar 2023 ★★★★★	Feb 2023 ★★★	Jan 2023 ★★★★★
Dec 2022 ★★★★★	Nov 2022 ★★★	Oct 2022 ★★★	Sep 2022 ★★★	Aug 2022 ★★★	Jul 2022 ★★★	Jun 2022 ★★★★★	May 2022 ★★★★★	Apr 2022 ★★★	Mar 2022 ★★★★★	Feb 2022 ★★★★★	Jan 2022 ★★★★★
Dec 2021 ★★★★★	Nov 2021 ★★★★★	Oct 2021 ★★★★★	Sep 2021 ★★★★★	Aug 2021 ★★★★★	Jul 2021 ★★★★★	Jun 2021 ★★★★★	May 2021 ★★★	Apr 2021 ★★★★★	Mar 2021 ★★★★★	Feb 2021 ★★★★★	Jan 2021 ★★★★★
Dec 2020 ★★★★★	Nov 2020 ★★★★★	Oct 2020 ★★★★★	Sep 2020 ★★★★★	Aug 2020 ★★★★★	Jul 2020 ★★★★★	Jun 2020 ★★★★★	May 2020 ★★★★★	Apr 2020 ★★★★★	Mar 2020 ★★★★★	Feb 2020 ★★★★★	Jan 2020 ★★★★★

Research Methodology for Valuing Companies

Overview

At the heart of our valuation system is a detailed projection of a company's future cash flows, resulting from our analysts' research. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into our globally standardized, proprietary discounted cash flow, or DCF, modeling templates. We use scenario analysis, depth competitive advantage analysis, and a variety of other analytical tools to augment this process. Moreover, we think analyzing valuation through discounted cash flows presents a better lens for viewing cyclical companies, high-growth firms, businesses with finite lives (e.g., mines), or companies expected to generate negative earnings over the next few years. That said, we don't dismiss multiples altogether but rather use them as supporting cross-checks for our DCF-based fair value estimates. We also acknowledge that DCF models offer their own challenges (including a potential proliferation of estimated inputs and the possibility that the method may miss shortterm market-price movements), but we believe these negatives are mitigated by deep analysis and our longterm approach.

Morningstar's equity research group ("we," "our") believes that a company's intrinsic worth results from the future cash flows it can generate. The Morningstar Rating for stocks identifies stocks trading at a discount or premium to their intrinsic worth—or fair value estimate, in Morningstar terminology. Five-star stocks sell for the biggest risk adjusted discount to their fair values, whereas 1-star stocks trade at premiums to their intrinsic worth.

Four key components drive the Morningstar rating: (1) our assessment of the firm's economic moat, (2) our estimate of the stock's fair value, (3) our uncertainty around that fair value estimate and (4) the current market price. This process ultimately culminates in our singlepoint star rating.

1. Economic Moat

The concept of an economic moat plays a vital role not only in our qualitative assessment of a firm's long-term investment potential, but also in the actual calculation of our fair value estimates. An economic moat is a structural feature that allows a firm to sustain excess profits over a

long period of time. We define economic profits as returns on invested capital (or ROIC) over and above our estimate of a firm's cost of capital, or weighted average cost of capital (or WACC). Without a moat, profits are more susceptible to competition. We have identified five sources of economic moats: intangible assets, switching costs, network effect, cost advantage, and efficient scale.

Companies with a narrow moat are those we believe are more likely than not to achieve normalized excess returns for at least the next 10 years. Wide-moat companies are those in which we have very high confidence that excess returns will remain for 10 years, with excess returns more likely than not to remain for at least 20 years. The longer a firm generates economic profits, the higher its intrinsic value. We believe low-quality, no-moat companies will see their normalized returns gravitate toward the firm's cost of capital more quickly than companies with moats.

When considering a company's moat, we also assess whether there is a substantial threat of value destruction, stemming from risks related to ESG, industry disruption, financial health, or other idiosyncratic issues. In this context, a risk is considered potentially value destructive if its occurrence would eliminate a firm's economic profit on a cumulative or midcycle basis. If we deem the probability of occurrence sufficiently high, we would not characterize the company as possessing an economic moat.

2. Estimated Fair Value

Combining our analysts' financial forecasts with the firm's economic moat helps us assess how long returns on invested capital are likely to exceed the firm's cost of capital. Returns of firms with a wide economic moat rating are assumed to fade to the perpetuity period over a longer period of time than the returns of narrow-moat firms, and both will fade slower than no-moat firms, increasing our estimate of their intrinsic value.

Our model is divided into three distinct stages:

Stage I: Explicit Forecast

In this stage, which can last five to 10 years, analysts make full financial statement forecasts, including items such as revenue, profit margins, tax rates, changes in workingcapital accounts, and capital spending. Based on these projections, we calculate earnings before interest,

after taxes (EBI) and the net new investment (NNI) to derive our annual free cash flow forecast.

Stage II: Fade

The second stage of our model is the period it will take the company's return on new invested capital—the return on capital of the next dollar invested ("RONIC")—to decline (or rise) to its cost of capital. During the Stage II period, we use a formula to approximate cash flows in lieu of explicitly modeling the income statement, balance sheet, and cash flow statement as we do in Stage I. The length of the second stage depends on the strength of the company's economic moat. We forecast this period to last anywhere from one year (for companies with no economic moat) to 10–15 years or more (for wide-moat companies). During this period, cash flows are forecast using four assumptions: an average growth rate for EBI over the period, a normalized investment rate, average return on new invested capital (RONIC), and the number of years until perpetuity, when excess returns cease. The investment rate and return on new invested capital decline until a perpetuity value is calculated. In the case of firms that do not earn their cost of capital, we assume marginal ROICs rise to the firm's cost of capital (usually attributable to less reinvestment), and we may truncate the second stage.

Stage III: Perpetuity

Once a company's marginal ROIC hits its cost of capital, we calculate a continuing value, using a standard perpetuity formula. At perpetuity, we assume that any growth or decline or investment in the business neither creates nor destroys value and that any new investment provides a return in line with estimated WACC.

Because a dollar earned today is worth more than a dollar earned tomorrow, we discount our projections of cash flows in stages I, II, and III to arrive at a total present value of expected future cash flows. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the WACC, which is a weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights.

3. Uncertainty Around That Fair Value Estimate

Morningstar's Uncertainty Rating is designed to capture the range of potential outcomes for a company's intrinsic value. This rating is used to assign the margin of safety required before investing, which in turn explicitly drives our stock star rating system. The Uncertainty Rating is aimed at identifying the confidence we should have in assigning a fair value estimate for a given stock.

Our Uncertainty Rating is meant to take into account anything that can increase the potential dispersion of future

Morningstar Equity Research Star Rating Methodology



Research Methodology for Valuing Companies

outcomes for the intrinsic value of a company, and anything that can affect our ability to accurately predict these outcomes. The rating begins with a suggested rating produced by a quantitative process based on the trailing 12-month standard deviation of daily stock returns. An analyst overlay is then applied, with analysts using the suggested rating, historical rating data, and their own knowledge of the company to inform them as they make the final Uncertainty Rating decision. Ultimately, the rating decision rests with the analyst. Analysts take into account many characteristics when making their final decision, including cyclical factors, operational and financial factors such as leverage, company-specific events, ESG risks, and anything else that might increase the potential dispersion of future outcomes and our ability to estimate those outcomes.

Our recommended margin of safety—the discount to fair value demanded before we'd recommend buying or selling the stock—widens as our uncertainty of the estimated value of the equity increases. The more uncertain we are about the potential dispersion of outcomes, the greater the discount we require relative to our estimate of the value of the firm before we would recommend the purchase of the shares. In addition, the Uncertainty Rating provides guidance in portfolio construction based on risk tolerance.

Our Uncertainty Ratings are: Low, Medium, High, Very High, and Extreme.

Margin of Safety

Qualitative Analysis	Uncertainty Ratings	★★★★★ Rating	★ Rating
Low	20% Discount	25% Premium	
Medium	30% Discount	35% Premium	
High	40% Discount	55% Premium	
Very High	50% Discount	75% Premium	
Extreme	75% Discount	300% Premium	


Our uncertainty rating is based on the interquartile range, or the middle 50% of potential outcomes, covering the 25th percentile–75th percentile. This means that when a stock hits 5 stars, we expect there is a 75% chance that the intrinsic value of that stock lies above the current market price. Similarly, when a stock hits 1 star, we expect there is a 75% chance that the intrinsic value of that stock lies below the current market price.

4. Market Price

The market prices used in this analysis and noted in the report come from exchange on which the stock is listed which we believe is a reliable source.

For more details about our methodology, please go to <https://shareholders.morningstar.com>

Morningstar Equity Research Star Rating Methodology



Morningstar Star Rating for Stocks

Once we determine the fair value estimate of a stock, we compare it with the stock's current market price on a daily basis, and the star rating is automatically re-calculated at the market close on every day the market on which the stock is listed is open. Our analysts keep close tabs on the companies they follow, and, based on thorough and ongoing analysis, raise or lower their fair value estimates as warranted.

Please note, there is no predefined distribution of stars. That is, the percentage of stocks that earn 5 stars can fluctuate daily, so the star ratings, in the aggregate, can serve as a gauge of the broader market's valuation. When there are many 5-star stocks, the stock market as a whole is more undervalued, in our opinion, than when very few companies garner our highest rating.

We expect that if our base-case assumptions are true the market price will converge on our fair value estimate over time generally within three years (although it is impossible to predict the exact time frame in which market prices may adjust).

Our star ratings are guideposts to a broad audience and individuals must consider their own specific investment goals, risk tolerance, tax situation, time horizon, income needs, and complete investment portfolio, among other factors.

The Morningstar Star Ratings for stocks are defined below:

★★★★★ We believe appreciation beyond a fair risk-adjusted return is highly likely over a multiyear time frame. Scenario analysis developed by our analysts indicates that the current market price represents an excessively pessimistic outlook, limiting downside risk and maximizing upside potential.

★★★★ We believe appreciation beyond a fair risk-adjusted return is likely.

★★★ Indicates our belief that investors are likely to receive a fair risk-adjusted return (approximately cost of equity).

★★ We believe investors are likely to receive a less than fair risk-adjusted return.

★ Indicates a high probability of undesirable risk-adjusted returns from the current market price over a multi-year time frame, based on our analysis. Scenario analysis by our analysts indicates that the market is pricing in an excessively optimistic outlook, limiting upside potential and leaving the investor exposed to Capital loss.

Other Definitions

Last Price: Price of the stock as of the close of the market of the last trading day before date of the report.

Capital Allocation Rating: Our Capital Allocation (or Stewardship) Rating represents our assessment of the quality of management's capital allocation, with particular emphasis on the firm's balance sheet, investments,

Research Methodology for Valuing Companies

and shareholder distributions. Analysts consider companies' investment strategy and valuation, balance sheet management, and dividend and share buyback policies. Corporate governance factors are only considered if they are likely to materially impact shareholder value, though either the balance sheet, investment, or shareholder distributions. Analysts assign one of three ratings: "Exemplary", "Standard", or "Poor". Analysts judge Capital Allocation from an equity holder's perspective. Ratings are determined on a forward looking and absolute basis. The Standard rating is most common as most managers will exhibit neither exceptionally strong nor poor capital allocation.

Capital Allocation (or Stewardship) analysis published prior to Dec. 9, 2020, was determined using a different process. Beyond investment strategy, financial leverage, and dividend and share buyback policies, analysts also considered execution, compensation, related party transactions, and accounting practices in the rating.

Capital Allocation Rating: Our Capital Allocation (or Stewardship) Rating represents our assessment of the quality of management's capital allocation, with particular emphasis on the firm's balance sheet, investments, and shareholder distributions. Analysts consider companies' investment strategy and valuation, balance sheet management, and dividend and share buyback policies. Corporate governance factors are only considered if they are likely to materially impact shareholder value, though either the balance sheet, investment, or shareholder distributions. Analysts assign one of three ratings: "Exemplary", "Standard", or "Poor". Analysts judge Capital Allocation from an equity holder's perspective. Ratings are determined on a forward looking and absolute basis. The Standard rating is most common as most managers will exhibit neither exceptionally strong nor poor capital allocation.

Capital Allocation (or Stewardship) analysis published prior to Dec. 9, 2020, was determined using a different process. Beyond investment strategy, financial leverage, and dividend and share buyback policies, analysts also considered execution, compensation, related party transactions, and accounting practices in the rating.

Sustainalytics ESG Risk Rating Assessment: The ESG Risk Rating Assessment is provided by Sustainalytics; a Morningstar company.

Sustainalytics' ESG Risk Ratings measure the degree to which company's economic value at risk is driven by environment, social and governance (ESG) factors.

Sustainalytics analyzes over 1,300 data points to assess a company's exposure to and management of ESG risks. In other words, ESG Risk Ratings measures a company's unmanaged ESG Risks represented as a quantitative score.

Unmanaged Risk is measured on an open-ended scale starting at zero (no risk) with lower scores representing less unmanaged risk and, for 95% of cases, the unmanaged ESG Risk score is below 50.

Based on their quantitative scores, companies are grouped into one of five Risk Categories (negligible, low, medium, high, severe). These risk categories are absolute, meaning that a 'high risk' assessment reflects a comparable degree of unmanaged ESG risk across all subindustries covered.

The ESG Risk Rating Assessment is a visual representation of Sustainalytics ESG Risk Categories on a 1 to 5 scale. Companies with Negligible Risk = 5 Globes, Low Risk = 4, Medium Risk = 3 Globes, High Risk = 2 Globes, Severe Risk = 1 Globe. For more information, please visit sustainalytics.com/esg-ratings/

Ratings should not be used as the sole basis in evaluating a company or security. Ratings involve unknown risks and uncertainties which may cause our expectations not to occur or to differ significantly from what was expected and should not be considered an offer or solicitation to buy or sell a security.

Risk Warning

Please note that investments in securities are subject to market and other risks and there is no assurance or guarantee that the intended investment objectives will be achieved. Past performance of a security may or may not be sustained in future and is no indication of future performance. A security's investment return and an investor's principal value will fluctuate so that, when redeemed, an investor's shares may be worth more or less than their original cost. A security's current investment performance may be lower or higher than the investment performance noted within the report. Morningstar's Uncertainty Rating serves as a useful data point with respect to sensitivity analysis of the assumptions used in our determining a fair value price.

General Disclosure

Unless otherwise provided in a separate agreement, recipients accessing this report may only use it in the country in which the Morningstar distributor is based. Unless stated otherwise, the original distributor of the report is Morningstar Research Services LLC, a U.S.A. domiciled financial institution.

This Report is for informational purposes, should not be the sole piece of information used in making an investment decision, and has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. This publication is intended to provide information to assist investors in making their

own investment decisions, not to provide investment advice to any specific investor. Therefore, investments discussed herein may not be suitable for all investors; investors must exercise their own independent judgment as to the suitability of such investments and recommendations in the light of their own investment objectives, experience, taxation status and financial position. Morningstar encourages Report recipients to read all relevant issue documents (e.g., prospectus) pertaining to the security concerned, including without limitation, information relevant to its investment objectives, risks, and costs before making an investment decision and when deemed necessary, to seek the advice of a financial, legal, tax, and/or accounting professional. The information, data, analyses and opinions presented herein are not warranted to be accurate, correct, complete or timely. Unless otherwise provided in a separate agreement, neither Morningstar, Inc. or the Equity Research Group represents that the report contents meet all of the presentation and/or disclosure standards applicable in the jurisdiction the recipient is located.

Except as otherwise required by law or provided for in a separate agreement, the analyst, Morningstar, Inc. and the Equity Research Group and their officers, directors and employees shall not be responsible or liable for any trading decisions, damages or other losses resulting from, or related to, the information, data, analyses or opinions within the report.

The Report and its contents are not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Morningstar, Inc. or its affiliates to any registration or licensing requirements in such jurisdiction.

Where this report is made available in a language other than English and in the case of inconsistencies between the English and translated versions of the report, the English version will control and supersede any ambiguities associated with any part or section of a report that has been issued in a foreign language. Neither the analyst, Morningstar, Inc., or the Equity Research Group guarantees the accuracy of the translations.

This report may be distributed in certain localities, countries and/or jurisdictions ("Territories") by independent third parties or independent intermediaries and/or distributors ("Distributors"). Such Distributors are not acting as agents or representatives of the analyst, Morningstar, Inc. or the Equity Research Group. In Territories where a Distributor distributes our report, the Distributor is solely responsible for complying with all applicable regulations, laws, rules, circulars, codes and guidelines established

Research Methodology for Valuing Companies

by local and/or regional regulatory bodies, including laws in connection with the distribution third-party research reports.

Conflicts of Interest

- ▶ No interests are held by the analyst with respect to the security subject of this investment research report.
- ▶ Morningstar, Inc. may hold a long position in the security subject of this investment research report that exceeds 0.5% of the total issued share capital of the security. To determine if such is the case, please click <http://msi.morningstar.com> and <http://mdi.morningstar.com>
- ▶ Analysts' compensation is derived from Morningstar, Inc.'s overall earnings and consists of salary, bonus and in some cases restricted stock.
- ▶ Neither Morningstar, Inc. or the Equity Research Group receives commissions for providing research nor do they charge companies to be rated.
- ▶ Morningstar's overall earnings are generated in part by the activities of the Investment Management and Research groups, and other affiliates, who provide services to product issuers.
- ▶ Morningstar employees may not pursue business and employment opportunities outside Morningstar within the investment industry (including but not limited to, working as a financial planner, an investment professional or investment professional representative, a broker-dealer or broker-dealer agent, a financial writer, reporter, or analyst) without the approval of Morningstar's Legal and if applicable, Compliance teams.
- ▶ Neither Morningstar, Inc. or the Equity Research Group is a market maker or a liquidity provider of the security noted within this report.
- ▶ Neither Morningstar, Inc. or the Equity Research Group has been a lead manager or co-lead manager over the previous 12-months of any publicly disclosed offer of financial instruments of the issuer.
- ▶ Morningstar, Inc.'s investment management group does have arrangements with financial institutions to provide portfolio management/investment advice some of which an analyst may issue investment research reports on. However, analysts do not have authority over Morningstar's investment management group's business arrangements nor allow employees from the investment management group to participate or influence the analysis or opinion prepared by them.
- ▶ Morningstar, Inc. is a publicly traded company (Ticker Symbol: MORN) and thus a financial institution the security of which is the subject of this report may own more than 5% of Morningstar, Inc.'s total outstanding shares. Please access Morningstar, Inc.'s proxy statement, "Security Ownership of Certain Beneficial Owners and Management" section <https://shareholders.morningstar.com/investor-relations/financials/sec-filings/default.aspx>

- ▶ Morningstar, Inc. may provide the product issuer or its related entities with services or products for a fee and on an arms' length basis including software products and licenses, research and consulting services, data services, licenses to republish our ratings and research in their promotional material, event sponsorship and website advertising.

Further information on Morningstar, Inc.'s conflict of interest policies is available from <http://global.morningstar.com/equitydisclosures>. Also, please note analysts are subject to the CFA Institute's Code of Ethics and Standards of Professional Conduct.

Risk Warning Please note that investments in securities are subject to market and other risks and there is no assurance or guarantee that the intended investment objectives will be achieved. Past performance of a security may or may not be sustained in future and is no indication of future performance. A security's investment return and an investor's principal value will fluctuate so that, when redeemed, an investor's shares may be worth more or less than their original cost. A security's current investment performance may be lower or higher than the investment performance noted within the report. For investments in foreign markets there are further risks, generally based on exchange rate changes or changes in political and social conditions.

For more information about Morningstar's methodologies, please visit global.morningstar.com/equitydisclosures

For a list of securities which the Equity Research Group currently covers and provides written analysis on please contact your local Morningstar office. In addition, for historical analysis of securities covered, including their fair value estimate, please contact your local office.

For recipients in Australia: This Report has been issued and distributed in Australia by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544; ASFL: 240892). Morningstar Australasia Pty Ltd is the provider of the general advice ('the Service') and takes responsibility for the production of this report. The Service is provided through the research of investment products.

To the extent the Report contains general advice it has been prepared without reference to an investor's objectives, financial situation or needs. Investors should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement before making any decision to invest. Refer to our Financial Services Guide (FSG) for more information at <http://www.morningstar.com.au/fsg.pdf>

For recipients in New Zealand: This report has been is-

sued and distributed by Morningstar Australasia Pty Ltd and/or Morningstar Research Ltd (together 'Morningstar'). This report has been prepared and is intended for distribution in New Zealand to wholesale clients only and has not been prepared for use by New Zealand retail clients (as those terms are defined in the Financial Markets Conduct Act 2013). The information, views and any recommendations in this material are provided for general information purposes only, and solely relate to the companies and investment opportunities specified within. Our reports do not take into account any particular investor's financial situation, objectives or appetite for risk, meaning no representation may be implied as to the suitability of any financial product mentioned for any particular investor. We recommend seeking financial advice before making any investment decision.

For recipients in Hong Kong: The Report is distributed by Morningstar Investment Management Asia Limited, which is regulated by the Hong Kong Securities and Futures Commission to provide services to professional investors only. Neither Morningstar Investment Management Asia Limited, nor its representatives, are acting or will be deemed to be acting as an investment professional to any recipients of this information unless expressly agreed to by Morningstar Investment Management Asia Limited.

For recipients in India: This investment research is issued by Morningstar Investment Adviser India Private Limited. Morningstar Investment Adviser India Private Limited is registered with SEBI as a Portfolio Manager (registration number INP000006156) and as a Research Entity (registration number INH000008686). Morningstar Investment Adviser India Private Limited has not been the subject of any disciplinary action by SEBI or any other legal/regulatory body. Morningstar Investment Adviser India Private Limited is a wholly owned subsidiary of Morningstar Investment Management LLC. In India, Morningstar Investment Adviser India Private Limited has one associate, Morningstar India Private Limited, which provides data-related services, financial data analysis, and software development. The research analyst has not served as an officer, director, or employee of the fund company within the last 12 months, nor have they or their associates engaged in market-making activity for the fund company. The ESG-related information, methodologies, tool, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar/Sustainalytics accepts no responsibility or liability whatsoever for the actions of third parties in this respect.

*The Conflicts of Interest disclosure above also applies to relatives and associates of Manager Research Analysts in

Research Methodology for Valuing Companies

India # The Conflicts of Interest disclosure above also applies to associates of Manager Research Analysts in India. The terms and conditions on which Morningstar Investment Adviser India Private Limited offers Investment Research to clients, varies from client to client, and are detailed in the respective client agreement.

For recipients in Japan: The Report is distributed by Ibbotson Associates Japan, Inc., which is regulated by Financial Services Agency, for informational purposes only. Neither Ibbotson Associates Japan, Inc., nor its representatives, are acting or will be deemed to be acting as an investment professional to any recipients of this information.

For recipients in Singapore: The Report is intended for Institutional Investor audiences and is distributed by Morningstar Investment Adviser Singapore Pte. Limited, which is licensed by the Monetary Authority of Singapore to provide financial advisory services in Singapore. Morningstar Investment Adviser Singapore Pte. Limited is the entity responsible for the creation and distribution of the research services described in this Report.

This content is provided for informational purposes only and may be shared or redistributed by Institutional Investors to their clients or other permitted persons, subject to obtaining the appropriate licence from Morningstar. Redistribution of this content is subject to any applicable conditions or limitations, including those agreed commercially or contractually with Morningstar. The person who shares or redistributes this content shall be solely responsible for compliance with all relevant legal and regulatory obligations in the jurisdictions in which the material is made available.

Investors should consult a financial adviser regarding the suitability of any investment product, taking into account their specific investment objectives, financial situation or particular needs, before making any investment decision.

Morningstar, Inc., and its affiliates rely on certain exemptions (Financial Advisers Regulations, Section 27(1)(e), Section 32B and 32C) to provide its investment research to recipients in Singapore.

For recipients in Korea: The report is distributed by Morningstar Korea Ltd., which has filed to the Financial Services Committee, for informational purposes only. Neither Morningstar Korea Ltd. nor its representatives are acting or will be deemed to be acting as an investment advisor to any recipients of this information.